ALAS1

Across TCGA pan-cancer cohorts, ALAS1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ALAS1 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ALAS1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ALAS1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LUAD, GBM, and HNSC are the cancer types where ALAS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.429	1.000	.008	9	view →
GBM	OS	Quartile	All	0.379	0.764	.002	7	view →
HNSC	DFS	Median	III,IV	0.590	0.900	.008	6	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.795	.020	6	view →
PDAC	DFS	Tertile	All	0.573	0.291	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ALAS1–LUAD (OS)

Open the LUAD breakdown →